NCT06525350View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

256

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 25, 2026

Study Completion Date

June 25, 2028

Conditions

Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression

Interventions

DRUG

Glumetinib tablets

An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor

DRUG

HB1801 (docetaxel, albumin-bound）

An improved new formulations of docetaxel

DRUG

Docetaxel

A chemotherapy drug

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06525350 - A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter